ReviewNature reviews. Drug discovery2022
Anti-obesity drug discovery: advances and challenges.
Review in Nature reviews. Drug discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 457 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
457 citing papers in PubMed, 7 syntheses or guidelines pooled it, 933 citations in OpenAlex.
- Incretin Dominance and Emerging Mechanisms in Obesity Pharmacotherapy: Insights from 275 Registered Clinical Trials (2019-2024).Therapeutic innovation & regulatory science · 2026Pooled it
- Hyperphagia in rare melanocortin-4 receptor pathway diseases: therapeutic options and assessing treatment response.Reviews in endocrine & metabolic disorders · 2025Pooled it
- Pooled it
- Effects of tirzepatide on weight management in patients with and without diabetes: a systematic review and meta-analysis.International journal of obesity (2005) · 2025Pooled it
- A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.Nature medicine · 2025 · on this mapPooled it
- Effects of Skeletal Muscle Hypertrophy on Fat Mass and Glucose Homeostasis in Humans and Animals: A Narrative Review with Systematic Literature Search.Sports medicine (Auckland, N.Z.) · 2025Pooled it
- Nutritional and functional outcomes in trials of nutrient-stimulated hormone-based therapy-A systematic mapping review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Pooled it
- Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.Signal transduction and targeted therapy · 2026Trial
- Efficacy and Safety of CKDB-322, a Combination ofNutrients · 2026Trial
- Impact of Setmelanotide on Metabolic Syndrome Risk in Patients With Bardet-Biedl Syndrome.The Journal of clinical endocrinology and metabolism · 2025Trial
- Long-acting PYYObesity (Silver Spring, Md.) · 2025Trial
- Safety, Tolerability, and Pharmacokinetics of a Novel Anti-obesity Agent, S-309309, in Healthy Adults with or Without Obesity.Clinical drug investigation · 2025Trial
- Gut microbiome and metabolic health: mechanisms and precision interventions.Gut microbes · 2026Review
- A novel bile salt hydrolase-producingGut microbes · 2026Article
- Design of INFORMUS, a pragmatic, randomized, double-blind, placebo-controlled study of cardiovascular outcomes with the extended-release, fixed-dose combination of naltrexone and bupropion.Obesity pillars · 2026Article
- Attitudes of Swedish primary care physicians toward GLP-1 receptor agonists for overweight and obesity: a cross-sectional survey.BMC primary care · 2026Article
- Palmitoylethanolamide in Human and Animal Obesity.Molecules (Basel, Switzerland) · 2026Review
- Psoriatic arthritis and obesity: a review of clinical burden and considerations for comprehensive care.RMD open · 2026Review
- Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight.International journal of obesity (2005) · 2026Article
- Article
397 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enormous progress has been made in the last half-century in the management of diseases closely integrated with excess body weight, such as hypertension, adult-onset diabetes and elevated cholesterol. However, the treatment of obesity itself has proven largely resistant to therapy, with anti-obesity medications (AOMs) often delivering insufficient efficacy and dubious safety. Here, we provide an overview of the history of AOM development, focusing on lessons learned and ongoing obstacles. Recent advances, including increased understanding of the molecular gut-brain communication, are inspiring the pursuit of next-generation AOMs that appear capable of safely achieving sizeable and sustained body weight loss.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.